Abstract: The present invention provides a novel fusion protein suitable for high expression and the production method thereof. The structure of the fusion protein is A-C1-K-(B-C2-K)n-D, wherein A is the upstream peptide; each of C1 and C2 is independently short peptides having 20-40 amino acids in length and containing no Lys in sequence; K is Lys; B is a linker; D is a downstream peptide; n is an integer of 3-30. The fusion protein is expressed with high efficiency and stability in host cells. The purification and enzymatic cleavage technology of the expression product is simple, which is able to produce a short peptide with high efficiency, and has very high value of industrialization.

Abstract: The present invention provides a novel fusion protein suitable to be expressed high effectively and the production method thereof. The structure of the fusion protein is A-C1-K-(B-C2-K)n-D, wherein A is the upstream peptide; each of C1 and C2 is independently short peptides having 20-40 amino acids in length and containing no Lys in sequence; K is Lys; B is a linker; D is a downstream peptide; n is an integer of 3-30. The fusion protein is able to express high effectively and stably in host cells. The purification and enzymatic cleavage technology of the expression product is simple, which is able to produce a short peptide high effectively, and has very high value of industrialization.

Abstract: The present inventions provides a pharmaceutical composition comprising a safe and efficient amount of OGP, a safe and efficient amount of G-CSF and a pharmaceutically acceptable carrier, wherein the molar ratio of OGP to G-CSF is from 0.25:1 to 100:1. According to the present invention, there is a good synergism between OGP and G-CSF. Thus the haematogenesis of G-CSF is greatly promoted. The invention also discloses the preparation method and usage of the pharmaceutical composition, especially in promoting the haematogenesis of G-CSF and the immune response of lymphocyte.

Abstract: This invention provides a novel monomeric insulin B27K-DTrI, B27K-destripeptide-Insulin) its composition and the method of preparation therefore. Highly pure B27K-DTrI-Insulin is monomeric (non-associative at high concentration and physiological pH) with in vivo bioactivity being 80% of that of native insulin. B27K-DTrI-Insulin can be produced by enzyme cleavage of a monomeric insulin precursor secreted by yeast instead of the less efficient enzyme transpeptidation as known in the prior art. The new method increases the total yield and is favorable for industrial production.